论文部分内容阅读
目的 探究TNF和TGF α在血液肿瘤性疾病中的变化和病情及预后的关系。方法 用放射免疫分析法检测了血液肿瘤性疾病患者 (63例 )和正常健康人 (3 0例 )血清TNF和TGF α水平 ,对治疗前后、病情变化进行了比较。结果 血液肿瘤性疾病患者治疗前TNF水平都明显高于正常组 (P <0 .0 1) ,治疗缓解后比治疗前明显降低 (P <0 .0 1)。急、慢性白血病和非何杰金氏淋巴瘤患者治疗前血清TGF α水平都明显高于正常组 (P <0 .0 5 ) ,而多发性骨髓瘤和骨髓增生异常综合症患者治疗前血清TGF α水平低于正常组 (P >0 .0 5 ) ,急、慢性白血病、非何杰金氏淋巴瘤和多发性骨髓瘤治疗缓解后比治疗前明显降低 (P <0 .0 1) ,骨髓增生异常综合症患者血清TGF α水平治疗后比治疗前降低但差异不显著 (P >0 .0 5 )。急、慢性白血病患者恶化后血清TNF和TGF α水平均升至治疗前水平。结论 检测血液肿瘤性疾病患者血清TNF和TGF α水平 ,有助于了解这种病人的病情变化及其预后。
Objective To explore the relationship between the changes of tumor necrosis factor and transforming growth factor-α (TGF-α) in hematological neoplasm and their prognosis. Methods Serum levels of TNF and TGFα were measured by radioimmunoassay in 63 patients with hematologic malignancies and 30 healthy individuals. The changes of the patients’ condition before and after treatment were compared. Results The level of TNF in patients with hematological neoplasm before treatment was significantly higher than that in the normal group (P <0.01). After treatment, the level of TNF was significantly lower than before treatment (P <0.01). Serum TGF-α levels in patients with acute, chronic leukemia and non-Hodgkin’s lymphoma before treatment were significantly higher than those in the normal group (P <0.05), while patients with multiple myeloma and myelodysplastic syndrome α levels were lower than those in the normal group (P> 0.05), acute and chronic leukemias, non-Hodgkin’s lymphoma and multiple myeloma were significantly lower than those before treatment (P <0.01), bone marrow The levels of serum TGF-α in patients with PDS were lower than those before treatment, but the difference was not significant (P> 0.05). Serum levels of TNF and TGFα in patients with acute and chronic leukemia after exacerbation rose to their pre-treatment levels. Conclusion Detection of serum tumor necrosis factor and transforming growth factor-α levels in patients with hematologic malignancies can help to understand the changes of these patients and their prognosis.